Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $13.79

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $13.79.

A number of equities analysts recently commented on MRNS shares. Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Truist Financial restated a “buy” rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 price objective (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC grew its stake in Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares during the period. Franklin Resources Inc. grew its position in Marinus Pharmaceuticals by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after purchasing an additional 49,589 shares during the period. Vanguard Group Inc. increased its stake in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares in the last quarter. abrdn plc acquired a new position in Marinus Pharmaceuticals during the fourth quarter worth $6,006,000. Finally, Superstring Capital Management LP bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at $5,027,000. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Stock Down 1.3 %

MRNS opened at $1.48 on Wednesday. The company has a debt-to-equity ratio of 5.68, a current ratio of 3.07 and a quick ratio of 2.93. Marinus Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $11.26. The company’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $5.37.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, hitting the consensus estimate of ($0.68). The company had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. As a group, sell-side analysts anticipate that Marinus Pharmaceuticals will post -1.87 earnings per share for the current year.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.